| | IgG increased | IgG4 increased | CA-II Abs positivity | AMY-α Ab positivity |
|---|
AIP | 58 (7/12)a | 58 (7/12)b | 83 (10/12)c | 83 (10/12)d |
CP | 17 (4/23) | 0 (0/23) | 9 (2/23) | 13 (3/23) |
ICP | 38 (10/26) | 8 (2/26) | 50 (13/26) | 31 (8/26) |
Acute pancreatitis | 27 (3/11) | (1/11) | 54 (6/11) | 18 (2/11) |
Pancreatic cancer | 10 (2/21) | 14 (3/21) | 29 (6/21) | 0 (0/21) |
SS | 67 (6/9) | 0 (0/9) | 67 (6/9) | 23 (2/9) |
T1DM | ND | 7 (3/40) | 32 (13/40) | 22 (9/40) |
Healthy subjects | 0 (0/45) | 2 (1/45) | 8 (4/45) | 2 (1/45) |
- Results are expressed as percentage (number of positive cases/total number of cases)
- Ab antibodies, AIP autoimmune pancreatitis, CP chronic pancreatitis, ICP idiopathic chronic pancreatitis, ND not determined, SS Sjögren’s syndrome, T1DM type 1 diabetes mellitus
- aAIP versus CP: 0.03; AIP versus pancreatic cancer: 0.002; AIP versus healthy subjects: <0.0001
- bAIP versus CP: <0.0001; AIP versus ICP: 0.001; AIP versus acute pancreatitis: 0.013; AIP versus pancreatic cancer: 0.008; AIP versus SS: 0.005; AIP versus T1DM: <0.0001; AIP versus healthy subjects: <0.0001
- cAIP versus CP: <0.0001; AIP versus ICP: 0.05; AIP versus pancreatic cancer: 0.002; AIP versus T1DM: 0.002; AIP versus healthy subjects: <0.0001
- dAIP versus CP: <0.0001; AIP versus ICP: 0.003; AIP versus acute pancreatitis: 0.002; AIP versus pancreatic cancer: <0.0001; AIP versus SS: 0.005; AIP versus T1DM: <0.0001; AIP versus healthy subjects: <0.0001
